Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Corbus Pharmaceuticals stock | $1.97

Own Corbus Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Corbus Pharmaceuticals Holdings, Inc is a biotechnology business based in the US. Corbus Pharmaceuticals shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around USD$7.2 million.

How to buy shares in Corbus Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Corbus Pharmaceuticals Find the stock by name or ticker symbol: CRBP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Corbus Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.97, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Corbus Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Corbus Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Corbus Pharmaceuticals share price

Use our graph to track the performance of CRBP stocks over time.

Corbus Pharmaceuticals shares at a glance

Information last updated 2020-09-25.
Latest market closeUSD$1.97
52-week rangeUSD$1.39 - USD$9.78
50-day moving average USD$5.7167
200-day moving average USD$6.2944
Wall St. target priceUSD$8.3
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.93

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corbus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corbus Pharmaceuticals price performance over time

Historical closes compared with the close of $1.97 from 2020-09-29

1 week (2020-09-23) 30.90%
1 month (2020-09-01) -77.89%
3 months (2020-06-30) -76.52%
6 months (2020-03-30) -64.25%
1 year (2019-09-30) -59.55%
2 years (2018-09-28) -73.91%
3 years (2017-09-29) -72.45%
5 years (2015-09-30) 25.48%

Corbus Pharmaceuticals financials

Revenue TTM USD$7.2 million
Gross profit TTM USD$-53,461,222
Return on assets TTM -82.52%
Return on equity TTM -240.39%
Profit margin 0%
Book value $0.6
Market capitalisation USD$125.8 million

TTM: trailing 12 months

Shorting Corbus Pharmaceuticals shares

There are currently 15.6 million Corbus Pharmaceuticals shares held short by investors – that's known as Corbus Pharmaceuticals's "short interest". This figure is 2.4% down from 16.0 million last month.

There are a few different ways that this level of interest in shorting Corbus Pharmaceuticals shares can be evaluated.

Corbus Pharmaceuticals's "short interest ratio" (SIR)

Corbus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corbus Pharmaceuticals shares currently shorted divided by the average quantity of Corbus Pharmaceuticals shares traded daily (recently around 1.9 million). Corbus Pharmaceuticals's SIR currently stands at 8.04. In other words for every 100,000 Corbus Pharmaceuticals shares traded daily on the market, roughly 8040 shares are currently held short.

However Corbus Pharmaceuticals's short interest can also be evaluated against the total number of Corbus Pharmaceuticals shares, or, against the total number of tradable Corbus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corbus Pharmaceuticals's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Corbus Pharmaceuticals shares in existence, roughly 190 shares are currently held short) or 0.2362% of the tradable shares (for every 100,000 tradable Corbus Pharmaceuticals shares, roughly 236 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Corbus Pharmaceuticals.

Find out more about how you can short Corbus Pharmaceuticals stock.

Corbus Pharmaceuticals share dividends

We're not expecting Corbus Pharmaceuticals to pay a dividend over the next 12 months.

Corbus Pharmaceuticals share price volatility

Over the last 12 months, Corbus Pharmaceuticals's shares have ranged in value from as little as $1.39 up to $9.78. A popular way to gauge a stock's volatility is its "beta".

CRBP.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals's is 1.5373. This would suggest that Corbus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Corbus Pharmaceuticals overview

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site